Regeneron Pharmaceuticals: What the Print Has to Prove Today
Filed Friday 30 October 2026 · 13:01 UTC · Entry no. 133036 · scored against the close · never edited
Earnings Preview · 30 October 2026
Where our screen stands going in
Screens compliant (both standards agree). A name values-conscious investors can weigh on the merits.
What the Street expects
Consensus looks for earnings of about $16.25 a share on revenue near $4.6B. Over the next twelve months analysts pencil in $62.82 of earnings per share against $40.44 over the last twelve, growth of about 55%. The median analyst target is $900 (range $730 to $1030), 2% above the $886.00 share price, across 27 analysts.
How it has traded on past prints
Across the last 25 reports, the shares moved an average of -0.1% in the five sessions after the print and +0.9% over twenty. After a beat the average follow-through was +0.7%; after a miss, +3.9%. Misses have not been punished more than beats were rewarded, so the headline number alone has been a poor guide to the reaction here; guidance and the call matter more. There is no reliable drift pattern: the first move has often faded, so chasing the gap has not paid.
Levels that matter
At $886.00 the shares sit -3% below the 52-week high of $859.34 and 50% above the low of $591.52 (110% of the way up the range). The 50-day average is $791.38, below the price. The 200-day average is $735.37, below the price.
Valuation going in
The shares trade about 14% below our fair-value estimate: a modest cushion. Our fair-value estimate is $1030.00 against the current share price of $886.00. The shares trade at 20.2 times trailing earnings and 13.0 times forward earnings. Revenue is growing about 17% with net margins near 28%.
Our stance
The name clears our screen; the print tells us whether the valuation is earning its keep.
What the flow says going in
Money has been flowing IN underneath a flat-to-lower price: quiet accumulation, the kind of positioning that tends to show up before a name moves, not after. (21-day Chaikin Money Flow +0.05, five-day price change -0.0%, as of 2026-10-29, desk flow model).
This is analysis, not financial advice. Always manage your risk.
How This Entry Scores
Every level named in a session brief is scored against the next scheduled close. Nothing is edited after filing: if a level breaks, the record shows it as filed, not as corrected. The desk's full scored history sits on the track record page.